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falciparum transmission intensity in Eastern 
Uganda
Daniel Ayo1, Bakar Odongo1, Joseph Omara1, Chiara Andolina2, Ole Mulder2, Sarah G. Staedke3 and 
Teun Bousema2,4*  
Abstract 
Background: Plasmodium falciparum is responsible for the vast majority of (severe) clinical malaria cases in most 
African settings. Other Plasmodium species often go undiagnosed but may still have clinical consequences.
Case presentation: Here, five cases of Plasmodium malariae infections from Eastern Uganda (aged 2–39 years) are 
presented. These infections were all initially mistaken for P. falciparum, but Plasmodium schizonts (up to 2080/µL) were 
identified by microscopy. Clinical signs included history of fever and mild anaemia.
Conclusion: These findings highlight the importance of considering non-falciparum species as the cause of clini-
cal malaria. In areas of intense P. falciparum transmission, where rapid diagnostic tests that detect only P. falciparum 
antigens are commonly used, non-falciparum malaria cases may be missed.
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Background
In 2019, an estimated 229 million cases and 409,000 
deaths due to malaria were reported globally [1]. Most of 
these occurred in sub-Saharan Africa, and were caused 
by Plasmodium falciparum. Thus, it is not surprising that 
P. falciparum remains the focus of malaria control pro-
grammes and most malaria research in Africa. Other 
Plasmodium species are endemic in sub-Saharan Africa, 
including Plasmodium ovale, Plasmodium vivax and 
Plasmodium malariae [2]. These non-falciparum spe-
cies also cause clinical symptoms, and lead sometimes to 
severe consequences. Chronic infections with P. malariae 
may last for years, and can cause severe complications 
in approximately 3% of cases, including nephrotic syn-
drome, splenomegaly and anaemia [3, 4]. Moreover, P. 
malariae infections have been observed following treat-
ment of P. falciparum infections with artemisinin-based 
combination therapy (ACT) [5, 6].
Different Plasmodium species can be differentiated by 
microscopy but this requires laboratory infrastructure 
and technical expertise. Infections with P. malariae are 
typically characterized by low parasitaemia [7] and the 
presence of rosette schizonts (daisy heads) and other par-
asite life-stages in the peripheral blood [8]. Plasmodium 
malariae is often missed or misdiagnosed by microscopy 
[9, 10]. However, polymerase chain reaction (PCR) sug-
gests a non-negligible prevalence of P. malariae infection, 
either alone or mixed with other species, in population 
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surveys in African countries, where prevalence of up to 
12% has been reported [11, 12].
Rapid diagnostic tests (RDTs), which are simple to 
use and require minimal training, are increasingly being 
used to diagnose malaria. In Africa, most RDTs detect 
histidine-rich protein 2 (HRP2), an antigen that is spe-
cific for P. falciparum; use of these HRP2 RDTs is likely 
to contribute further to under-diagnosis of P. malariae 
infections.
Here, five cases are presented of symptomatic, uncom-
plicated P. malariae. These cases were coming from an 
area of intense P. falciparum transmission in Eastern 
Uganda and were initially misdiagnosed as P. falciparum 
by microscopy.
Case presentation
Patients described in this case report presented at either 
Masafu General Hospital or Nagongera Health Centre 
IV. Masafu General Hospital is a district referral facility 
in Busia District, an area in south-eastern Uganda that 
borders Kenya and Lake Victoria, where transmission of 
P. falciparum is perennial and intense [13]. Nagongera 
Health Centre IV in located in Nagongera sub-county in 
Tororo district. Nagongera sub-county is predominantly 
a rural setting, with traditionally very high malaria trans-
mission [14]. Between 2019 and 2020 the total Outpa-
tient Department treatment (OPD) attendance in Masafu 
General Hospital was 40,471, whilst in Nagongera Health 
Centre IV 18,624 [15].
In both settings, hospital and health centre, malaria 
diagnosis is routinely performed by HRP-2 based rapid 
diagnostic test (Standard Q Malaria Pf Ag, SD Biosensor, 
South Korea). However, as part of a research study on P. 
falciparum, clinic technicians all received formal micros-
copy training and thick and thin blood films were used 
for malaria diagnosis, instead of RDTs. Haemoglobin 
measurements were performed by Hemocue™ (haemo-
globinometer, Angelholm, Sweden).
Case‑patient 1
On January 30th 2020, a 15-year-old male presented to 
the OPD with history of fever, headache and joint pain 
for 3 days with no evidence of severe malaria or danger 
signs. At initial presentation, he had an axillary tempera-
ture of 36.8  °C and his physical examination was within 
normal limits. Malaria parasites were reported on the 
thick and thin blood film. By thick blood smear, total par-
asite count was 896 parasites/μL; malaria schizonts were 
observed at 176 parasites/μL (and included in the total 
parasite density estimate). Haemoglobin concentration 
was 12.3 g/dL. The patient was diagnosed with P. falcipa-
rum malaria.
Case‑patient 2
On February 19th 2020, a 20-year-old female presented 
to the OPD with history of fever for 3 days and headache, 
weakness and joint pain for 2 days. Her temperature on 
admission was 37.2 °C and her physical examination did 
not show abnormalities. After reading the thick blood 
film, malaria infection was diagnosed with a total of 2288 
parasites/μL (2080 schizonts/μL). Mild anaemia was 
detected with haemoglobin of 10.8 g/dL. The patient was 
diagnosed with P. falciparum malaria.
Case‑patient 3
On February 27th 2020, a 39-year-old female presented 
to the OPD with history of fever and joint pain for 2 days 
and headache, weakness and low back pain for 4  days. 
Her axillary temperature on admission was 37.0  °C and 
she was diagnosed with uncomplicated P. falciparum 
malaria based on a thick blood film with 336 parasites/
μL (272 schizonts/μL). Mild anaemia was detected with 
haemoglobin of 9.5 g/dL.
Case‑patient 4
On March 3rd 2020, a 2-year-old boy presented to the 
outpatient department with persistent vomiting, anorexia 
and headache. He had an axillary temperature of 38.3 °C. 
Microscopy slides were interpreted as P. falciparum/P. 
malariae mixed infection based on presence of 32 ring-
stage parasites/μL and 520 schizonts/μL for P. falciparum 
and one trophozoite “band form” for P. malariae. Hae-
moglobin was 7.8 g/dL. The patient was diagnosed with 
uncomplicated mixed species malaria infection.
Case‑patient 5
On April 29th 2020, a 14-year-old male with mild symp-
toms of fever, headache, joint pain and anorexia pre-
sented to Nagongera Health Center IV, Tororo district. 
He had an axillary temperature of 37.4  °C. Malaria was 
diagnosed by microscopy with 4016 parasites/μL (96 sch-
izonts/μL). Haemoglobin was 11.1 g/dL. The patient was 
diagnosed with uncomplicated P. falciparum malaria.
All five cases were treated for uncomplicated P. falcipa-
rum infection according to national Ugandan treatment 
guidelines with artemether lumefantrine 20  mg/120  mg 
twice per day for 3  days and discharged home [16]. 
Although there are some reports of persisting P. malar-
iae parasites after artemether-lumefantrine [5, 17], sug-
gestive of reduced treatment efficacy for this species, 
most available data support the use of artemether-lume-
fantrine for P. malariae [18, 19]. Thick and thin smears 
were re-read by expert microscopists and representa-
tive images taken (Fig.  1). Parasite DNA was extracted 
from fixed Giemsa-stained thick and thin smears using a 
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modified protocol for isolating genomic DNA from dried 
blood spots  (QIAamp®DNA Micro kit, cat numb. 56304) 
[20]. Plasmodium speciation was performed using modi-
fied methods described by Snounou et  al. [21]. Plasmo-
dium malariae parasite DNA was detected in material 
from all slides; P. falciparum was also detected for case 4 
(Table 1).
Discussion and conclusions
In these five symptomatic malaria cases, P. malariae was 
the most likely cause of the clinical symptoms. All cases 
were classified as uncomplicated malaria, although they 
presented with anaemia, a condition that is often asso-
ciated with chronic infection with P. malariae [3, 4]. 
In four cases, P. falciparum infection was initially diag-
nosed. Only after an expert microscopist reviewed the 
blood slides was P. malariae identified as the infecting 
species. The presence of symptomatic P. malariae mono-
infections has implications for the use of HRP-2 RDTs. 
In both of the study settings, HRP-2 RDTs are routinely 
used to diagnose malaria. Since non-falciparum Plas-
modium species do not express HRP-2 antigen, at least 
four of these cases would presumably have been missed 
in routine practice and would not have received malaria 
treatment.
he cases presented here all reported to the health facili-
ties within a relatively short 13-week period. No effort 
is made to systematically investigate for non-falciparum 
malaria among individuals presenting with suspected 
malaria under standard care. This suggests that a con-
siderable number of patients may present with uncom-
plicated non-falciparum malaria in this setting. The P. 
malariae cases reported here were older than typical P. 
falciparum cases in the area [22], which could be the con-
sequence of a lower force of infection of non-falciparum 
malaria, older age at first infection, and higher average 
age at clinical presentation. However, other studies found 
P. malariae infections predominantly in children [23, 24], 
further highlighting the need for research into the clini-
cal burden of non-falciparum malaria in African settings. 
Fig. 1 Features of Plasmodium malariae parasites in thin and thick 
blood smears. A typical band form mature trophozoite. × 10 ocular, 
× 100 magnification, thin smear. B young trophozoite. Pictures A, B 
taken with a smart phone camera. C, D: “daisy shape” schizonts. × 
10 ocular, × 100 magnification, thin film. E, F: schizonts. × 10 ocular, 
× 100 magnification, thick smear. C–F: Pictures taken with Axio Cam 
MRc-5, Zeiss, Germany. Blood smears were stained with 10% Giemsa 
solution
Table 1 Patient characteristics at presentation
a Density per microlitre of blood













1 15 Male 36.8 Headache 3d, joint pain 2d, 
fever
12.3 720 176 Pf Pm
2 20 Female 37.2 Headache 2d, general body 
weakness and joint pain 3d, 
fever 3d
10.8 208 2080 Pf Pm
3 39 Female 37.0 Fever and joint pain 2d, 
general body weakness, 
headache, backache 4d
9.5 64 272 Pf Pm
4 2 Male 38.3 Persistent vomiting, anorexia, 
fever, headache
7.8 32 520 Pf + Pm Pm/Pf
5 14 Male 37.4 Headache, fever 3d, joint pain, 
anorexia
11.1 3920 96 Pf Pm
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Identifying the species of Plasmodium infections using 
molecular diagnostic techniques is needed to quantify 
the burden of malaria in areas where multiple species 
may be present.
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